Literature DB >> 20309530

Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys.

Pierre Pouget1, Nicolas Wattiez, Sophie Rivaud-Péchoux, Bertrand Gaymard.   

Abstract

BACKGROUND: Ketamine, a non-competitive N-methyl-D: -aspartic acid antagonist, has been widely used for anaesthetic purposes. At sub-anaesthetic dosage, it induces a dissociative state similar to schizophrenia. The discovery of this effect on dissociative state has led to its use as a pharmacological model of schizophrenia and has also been responsible for its illegal use as a recreational drug. Whereas the former has provided invaluable information, the latter has demonstrated that repeated administration of ketamine induces tolerance. Surprisingly, a review of the relevant literature shows that tolerance to sub-anaesthetic doses of ketamine is largely unreported in neuropharmacological studies.
METHODS: In order to investigate this caveat, we have performed a post hoc analysis of the behavioural effects induced by repeated injections of sub-anaesthetic doses of ketamine observed in five consecutive monkeys performing two oculomotor tasks. Ketamine effects were quantified by the animals' performances and latencies in a prosaccade and an antisaccade task, two oculomotor paradigms that are impaired after ketamine administration.
RESULTS: Although the result of the initial injections confirmed a clear behavioural effect of ketamine injections in all monkeys, subsequent administrations showed that a tolerance eventually appeared in all monkeys. The profile of this tolerance exhibited however a large inter-subject variability.
CONCLUSIONS: Psychopharmacological experiments using ketamine as a pharmacological model of psychosis should therefore consider the kinetic and time course of these effects in each individuals and take them into account in the design of experimental protocols.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20309530     DOI: 10.1007/s00213-010-1797-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes.

Authors:  Y Yanagihara; S Kariya; M Ohtani; K Uchino; T Aoyama; Y Yamamura; T Iga
Journal:  Drug Metab Dispos       Date:  2001-06       Impact factor: 3.922

2.  Journey through the K-hole: phenomenological aspects of ketamine use.

Authors:  L Muetzelfeldt; S K Kamboj; H Rees; J Taylor; C J A Morgan; H V Curran
Journal:  Drug Alcohol Depend       Date:  2008-03-19       Impact factor: 4.492

3.  Acute and chronic effects of ketamine on semantic priming: modeling schizophrenia?

Authors:  Ana Stefanovic; Brigitta Brandner; Elissa Klaassen; Roman Cregg; Mayavaty Nagaratnam; Lesley M Bromley; Ravi K Das; Susan L Rossell; Celia J A Morgan; H Valerie Curran
Journal:  J Clin Psychopharmacol       Date:  2009-04       Impact factor: 3.153

4.  Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors.

Authors:  B A Orser; P S Pennefather; J F MacDonald
Journal:  Anesthesiology       Date:  1997-04       Impact factor: 7.892

5.  Ketamine induces failure of the oculomotor neural integrator in the cat.

Authors:  E Godaux; G Cheron; P Mettens
Journal:  Neurosci Lett       Date:  1990-08-14       Impact factor: 3.046

Review 6.  Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures.

Authors:  Bruce I Turetsky; Monica E Calkins; Gregory A Light; Ann Olincy; Allen D Radant; Neal R Swerdlow
Journal:  Schizophr Bull       Date:  2006-11-29       Impact factor: 9.306

7.  Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia.

Authors:  Gary Gilmour; Elsa Y Pioli; Sophie L Dix; Janice W Smith; Michael W Conway; Wendy T Jones; Sally Loomis; Rebecca Mason; Shahram Shahabi; Mark D Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2009-05-07       Impact factor: 4.530

Review 8.  Ketamine.

Authors:  B Sinner; B M Graf
Journal:  Handb Exp Pharmacol       Date:  2008

9.  Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities?

Authors:  A D Radant; T A Bowdle; D S Cowley; E D Kharasch; P P Roy-Byrne
Journal:  Neuropsychopharmacology       Date:  1998-11       Impact factor: 7.853

10.  Effects of droperidol, pentobarbital, and ketamine on myogenic transcranial magnetic motor-evoked responses in humans.

Authors:  C J Kalkman; J C Drummond; P M Patel; T Sano; R M Chesnut
Journal:  Neurosurgery       Date:  1994-12       Impact factor: 4.654

View more
  13 in total

1.  Ketamine Alters Outcome-Related Local Field Potentials in Monkey Prefrontal Cortex.

Authors:  Kevin J Skoblenick; Thilo Womelsdorf; Stefan Everling
Journal:  Cereb Cortex       Date:  2015-06-03       Impact factor: 5.357

2.  Evidence for spatial tuning of movement inhibition.

Authors:  Nicolas Wattiez; Tymothée Poitou; Sophie Rivaud-Péchoux; Pierre Pouget
Journal:  Exp Brain Res       Date:  2016-02-29       Impact factor: 1.972

3.  Ketamine Tolerance in Sprague-Dawley Rats after Chronic Administration of Ketamine, Morphine, or Cocaine.

Authors:  Samantha A Gerb; Jemma E Cook; Alexandria E Gochenauer; Camille S Young; Lindak K Fulton; Andrew W Grady; Kevin B Freeman
Journal:  Comp Med       Date:  2019-01-29       Impact factor: 0.982

4.  Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Christine Blasey; Keith Sudheimer; Jaspreet Pannu; Heather Pankow; Jessica Hawkins; Justin Birnbaum; David M Lyons; Carolyn I Rodriguez; Alan F Schatzberg
Journal:  Am J Psychiatry       Date:  2018-08-29       Impact factor: 18.112

5.  Rapid Recovery and Short Duration Anesthesia after Low Dose Ketamine and High Dose Dexmedetomidine in Rhesus Macaques (Macaca mulatta).

Authors:  Kristin E Killoran; Courtney A Walsh; Jennifer L Asher; Molly B Tarleton; Steven R Wilson
Journal:  J Am Assoc Lab Anim Sci       Date:  2021-03-17       Impact factor: 1.232

6.  Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism.

Authors:  Valentina Gigliucci; Grainne O'Dowd; Sheena Casey; Danielle Egan; Sinead Gibney; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

7.  Ketamine-Induced Hallucinations.

Authors:  Albert R Powers; Mark G Gancsos; Emily S Finn; Peter T Morgan; Philip R Corlett
Journal:  Psychopathology       Date:  2015-09-12       Impact factor: 1.944

8.  Ketamine-Induced Alteration of Working Memory Utility during Oculomotor Foraging Task in Monkeys.

Authors:  Ryo Sawagashira; Masaki Tanaka
Journal:  eNeuro       Date:  2021-04-06

9.  Effects of subanesthetic ketamine and (2R,6R) hydroxynorketamine on working memory and synaptic transmission in the nucleus reuniens in mice.

Authors:  Priyodarshan Goswamee; Remington Rice; Elizabeth Leggett; Fan Zhang; Sofia Manicka; Joseph H Porter; A Rory McQuiston
Journal:  Neuropharmacology       Date:  2022-01-20       Impact factor: 5.250

10.  The Effects of Ketamine on the Gut Microbiome on CD1 Mice.

Authors:  Samantha A Gerb; Ryan J Dashek; Aaron C Ericsson; Rachel Griffin; Craig L Franklin
Journal:  Comp Med       Date:  2021-07-23       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.